Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/Simvastatin vs Atorvastatin in T2DM with Hypercholesterolemia
NCT00110435Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- May 2005
- Primary completion
- Dec 2005
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial of Vytorin in hypercholesterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: Percent reduction in LDL-C from baseline at 6 weeks. Started May 2005; status: completed.
02
Drugs
Vytorin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00110435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110435.